O
IMCR icon

OrbiMed’s Immunocore IMCR Stock Holding History

OrbiMed’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-131,100
Closed -$4.89K – 139
2022
Q2 		$4.89K Buy
131,100
+3,000
+2% +$97.4K 0.09% 112
2022
Q1 		$3.83M Buy
+128,100
New +$3.23M 0.06% 125

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

OrbiMed's IMCR Position: Q3 2022 in Review

OrbiMed sold out of Immunocore (IMCR) in Q3 2022, closing a stake of 131,100 shares — an estimated $4.89K sold.

OrbiMed first reported a position in IMCR in Q1 2022 and held it in 2 quarters. The position peaked at $3.83M in Q1 2022. 86 funds tracked by Wall St. Rank hold IMCR as of Q3 2022.

  • OrbiMed reported no remaining Immunocore position as of Q3 2022 after selling out during the quarter.
  • OrbiMed sold 131,100 Immunocore shares in Q3 2022, an estimated $4.89K.
  • OrbiMed first reported a position in Immunocore in Q1 2022 and held it in 2 quarters.
  • OrbiMed's Immunocore position peaked at $3.83M in Q1 2022.
  • 86 funds tracked by Wall St. Rank held Immunocore as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.